Investment Thesis
KalVista demonstrates strong revenue growth (+294% YoY) and maintains exceptional liquidity ($243.5M cash, 7.22x current ratio) with low debt (0.31x leverage), providing a ~2 year cash runway. However, severe operating losses (-$154.7M) with negative free cash flow (-$128.8M) and critically thin equity ($17M) against massive asset base ($339.9M) create substantial execution risk until the company achieves profitability.
Strengths
- Exceptional revenue growth of 294% year-over-year demonstrates strong market traction
- Fortress balance sheet with $243.5M cash (71% of total assets) and low debt burden (0.31x debt-to-equity)
- Superior liquidity ratios (7.22x current, 7.21x quick) provide substantial operational flexibility and 2-year burn runway
Risks
- Severe cash burn of $127M operating cash flow and -$128.8M free cash flow with only $13.7M revenue limits runway without major inflection
- Critically undercapitalized with only $17M stockholders equity against $339.9M liabilities creates vulnerability to adverse events
- Pharmaceutical pre-profitability model carries execution risk; company must demonstrate path to gross margin sustainability and operating leverage
Key Metrics to Watch
- Revenue growth trajectory and gross margin emergence
- Monthly cash burn rate trend relative to revenue acceleration
- Operating cash flow inflection point toward positive territory
Financial Metrics
Revenue
13.7M
Net Income
-158.9M
EPS (Diluted)
$-2.97
Free Cash Flow
-128.8M
Total Assets
339.9M
Cash
243.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-1,129.5%
Net Margin
-1,160.0%
ROE
-934.8%
ROA
-46.7%
FCF Margin
-940.5%
Balance Sheet & Liquidity
Current Ratio
7.22x
Quick Ratio
7.21x
Debt/Equity
0.31x
Debt/Assets
95.0%
Interest Coverage
-313.88x
Long-term Debt
5.3M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-12T00:03:26.499956 |
Data as of: 2025-09-30 |
Powered by Claude AI